HD-OPM Archive
Topics › Cancer

Personalized mRNA vaccine succeeds in phase 3 melanoma trial after ~50% phase 2 benefit

Louis Nervegna · Aug 20, 2026 · ♥ 12 reactions · 12 comments · original Facebook post
CancerInfections & vaccines
AI summary & key facts

A personalized mRNA vaccine plus Keytruda improved recurrence-free and distant metastasis-free survival in a phase 3 trial of more than 1,100 patients with melanoma. The earlier phase 2 trial showed roughly a 50% reduction in recurrence or death at 5 years. Approval might come as early as 2027, and trials are under way in other cancers.

It looks like there has just been a major breakthrough in the treatment of aggressive melanoma skin cancer.

An individualized mRNA cancer vaccine just succeeded in a large phase 3 trial. The previous phase 2 trial had shown a 50% reduction in recurrence or deaths at 5 years, and it is looking like the phase 3 trial may have just corroborated those earlier results. This was in comparison to existing standard of care.

If there was indeed such a large reduction in recurrence and deaths, this therapy might be approved/available as soon as 2027.

The real promise here is its application to all different kinds of cancers… beyond just melanoma.

There are on-going clinical trials in non-small cell lung cancer, as well as in kidney cancer and bladder cancer.

See this additional post:
↪ Personalized mRNA melanoma vaccine could extend to other cancers, with trials ongoing

#melanomaHD #cancerHD #mrnaHD #vaccinesHD #merckHD #modernaHD

Research cited

A Cancer Vaccine Made From Your Own Tumor?

This could be a defining moment in cancer treatment.

A personalized mRNA cancer vaccine, custom-built from the mutations in an individual patient’s tumor, has now succeeded in a large Phase III melanoma trial.

This isn’t just another promising early study. More than 1,100 patients participated, and the combination of the personalized vaccine plus Keytruda significantly improved both recurrence-free survival and distant metastasis-free survival.

And we already have five-year data from the earlier randomized trial showing a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death.

The vaccine isn’t FDA-approved yet. But if the full Phase III data confirm these findings and regulatory review proceeds smoothly, we could potentially see access for appropriate melanoma patients as early as 2027.

Even more exciting: this technology is being studied in other cancers.

In this video, I explain what happened, how a vaccine can actually be personalized to someone’s cancer, and why I believe this is a development worth watching very closely.

Personalized cancer vaccines have been a goal for decades. We may finally be watching them become a clinical reality.

Merck.comMerck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients…First and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant melanoma setting The Companies plan to present data at an upcoming international medical meeting and will engage with regulators on filing submissions for intismeran…merck.com
← newer: Personalized mRNA melanoma vaccine could extend to other canolder: Daily tomatoes and tomato sauce reduced liver fat in fatty l →